Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Perrysburg, Ohio, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Although some official bounties have soared well into the billions, none have yet to surpass that of the Pirate King himself, Gol D. Roger. However, this may change in the near future of the ...

SINGAPORE – The 3,047 F&B closures in 2024 was an almost-20-year record high. This was surpassed only by the year 2005, which saw 3,352 restaurant closures. But it was not all doom and gloom as ...

It features a robust annual credit on eligible Hilton spending, plus high ongoing rewards and automatic Gold Status. What you won't get, however, is a complimentary anniversary night. Many or all ...

At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic ...

CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...